🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Qinghai Red Cross Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Qinghai Red Cross Hospital as lead sponsor. Synced 26 Sep 2026
6Current trials
5Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Qinghai Red Cross Hospital is the lead sponsor of 6 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Mecobalamin and Olanzapine. The most-studied condition is Cancer.

ClinicalTrials.gov trials by status

  • Recruiting583%
  • Not yet open117%

Trials by phase

  • Phase 3350%
  • Phase EARLY_PHASE1117%
  • Observational117%
  • Phase 2117%
01

Clinical trials sponsored by Qinghai Red Cross Hospital

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain
NCT07489625 · ClinicalTrials.gov ↗ · Refractory Cancer Pain, Cancer Pain
Phase EARLY_PHASE1 Recruiting 2026-08 China
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
NCT06338683 · ClinicalTrials.gov ↗ · Advanced Cancer, Olanzapine, Progression Free Survival
Phase 3 Recruiting 2024-03 China
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT06915389 · ClinicalTrials.gov ↗ · Gastric Cancer, Immunotherapy, Adverse Event
Observational Recruiting 2025-02 China
Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy
NCT07423390 · ClinicalTrials.gov ↗ · Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Chemotherapy-induced
Phase 3 Recruiting 2026-02 China
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
NCT06859190 · ClinicalTrials.gov ↗ · Cancer, Insomnia
Phase 3 Recruiting 2025-03 China
Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy
NCT06891521 · ClinicalTrials.gov ↗ · Cancer, Adverse Events
Phase 2 Not yet open 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Qinghai Red Cross Hospital trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Qinghai Red Cross Hospital trials

14 conditions
Cancer2Refractory Cancer Pain1Cancer Pain1Advanced Cancer1Olanzapine1Progression Free Survival1Gastric Cancer1Immunotherapy1Adverse Event1Metabonomics1Peripheral Neuropathy Due to Chemotherapy1Peripheral Neuropathy, Chemotherapy-induced1Insomnia1Adverse Events1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China65

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Cancer

SponsorTrials
GRAIL4
Peking University Cancer Hospital & Institute4
Our Lady's Hospice and Care Services3
Conjupro Biotherapeutics3
University of Dublin, Trinity College2
Replimune2
Tempus AI2
Elephas2
First Hospital of China Medical University2
Wuxi People's Hospital2

Sponsors with the most current trials registered for this condition.

06

Questions about Qinghai Red Cross Hospital trials

How many clinical trials does Qinghai Red Cross Hospital sponsor?

Qinghai Red Cross Hospital is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Qinghai Red Cross Hospital trials recruiting?

Yes. 5 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Qinghai Red Cross Hospital testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Mecobalamin (1) and Olanzapine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.